Cancer Family
Carcinoma
CI-CAN-00000114Explore in graph →
7,369 active trials118 approved drugs1,149 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000114Explore in graph →
Clinical trials
25,729 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3,405)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07178795 | A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC | recruiting | Phase 3 | 440 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06144164 | A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer | recruiting | Phase 3 | 285 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 10, 2025 |
| clinicaltrials |
| NCT05929768 | Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | recruiting | Phase 3 | 2,400 | SWOG Cancer Research NetworkNETWORK | 3 | Nov 5, 2025 | clinicaltrials |
| NCT07103668 | A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients | recruiting | Phase 3 | 150 | Suzhou Immunofoco Biotechnology Co., LtdINDUSTRY | 1 | Oct 23, 2025 | clinicaltrials |
| NCT06699212 | A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases(ECLIPSE) | recruiting | Phase 3 | 412 | Rakuten Medical, Inc.INDUSTRY | 3 | Oct 15, 2025 | clinicaltrials |
| NCT02000089 | The Cancer of the Pancreas Screening-5 CAPS5)Study(CAPS5) | recruiting | Phase 3 | 9,000 | Johns Hopkins UniversityOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT03418961 | S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity | recruiting | Phase 3 | 491 | SWOG Cancer Research NetworkNETWORK | 4 | Oct 8, 2025 | clinicaltrials |
| NCT06817161 | Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovarian Cancer:(ESTANVO) | recruiting | Phase 3 | 116 | Centre Francois BaclesseOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT04111978 | MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)(MATAO) | recruiting | Phase 3 | 540 | Swiss GO Trial GroupNETWORK | 3 | Sep 29, 2025 | clinicaltrials |
| NCT05760612 | Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab | recruiting | Phase 3 | 300 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT06644937 | Single-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence | recruiting | Phase 2 / Phase 3 | 30 | Zhujiang HospitalOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT06732323 | A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer | recruiting | Phase 3 | 504 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT07186621 | Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC | recruiting | Phase 3 | 286 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT07155525 | Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas(NBCA-MS) | recruiting | Phase 3 | 194 | Minia UniversityOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06241612 | Individualized Elective Neck Irradiation in NPC Patients | recruiting | Phase 3 | 470 | Sun Yat-sen UniversityOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT06840782 | First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.(OliGRAIL) | recruiting | Phase 3 | 124 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT05278052 | Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLC(TARGET-02) | recruiting | Phase 3 | 190 | Tata Memorial HospitalOTHER_GOV | 1 | Sep 10, 2025 | clinicaltrials |
| NCT04510597 | Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial(PROBE) | recruiting | Phase 3 | 364 | SWOG Cancer Research NetworkNETWORK | 1 | Sep 9, 2025 | clinicaltrials |
| NCT07150663 | Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer | recruiting | Phase 3 | 134 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 8, 2025 | clinicaltrials |
| NCT07018661 | [18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric Cancer(PLASTIC-3) | recruiting | Phase 2 / Phase 3 | 250 | Leiden University Medical CenterOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT06177301 | Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC | recruiting | Phase 3 | 266 | Fudan UniversityOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT06492460 | 2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma | recruiting | Phase 3 | 422 | Sun Yat-sen UniversityOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT06095141 | Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency(PTCA199-6) | recruiting | Phase 2 / Phase 3 | 30 | Fudan UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06250972 | Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer(PTCA199-11) | recruiting | Phase 3 | 210 | Fudan UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06417008 | A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer | recruiting | Phase 2 / Phase 3 | 1,080 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Aug 1, 2025 | clinicaltrials |
| NCT06841172 | Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC | recruiting | Phase 3 | 132 | Shandong Cancer Hospital and InstituteOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT06537154 | NEO-BLAST: Neoadjuvant Therapy for Bladder Cancer Followed by Active Surveillance vs Treatment(NEO-BLAST) | recruiting | Phase 2 / Phase 3 | 688 | Peter BlackOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT06734702 | Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer | recruiting | Phase 3 | 497 | Sun Yat-sen UniversityOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT07067749 | Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer(TEMPO-MIBC) | recruiting | Phase 3 | 92 | University of Rome Tor VergataOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT07052669 | Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC | recruiting | Phase 3 | 311 | Sun Yat-sen UniversityOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT04574960 | Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL)(NAUTICAL) | recruiting | Phase 3 | 14 | University Health Network, TorontoOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT06738251 | A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma | recruiting | Phase 3 | 402 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 17, 2025 | clinicaltrials |
| NCT06457906 | SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC(SHARP) | recruiting | Phase 3 | 340 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT07062263 | Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients(TAB-2) | recruiting | Phase 3 | 220 | Tata Memorial CentreOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT06228079 | Adjuvant vs Surgery Only in Early-stage Recurrent NPC | recruiting | Phase 3 | 176 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT07050043 | Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC(LEDANG) | recruiting | Phase 3 | 123 | Dr Arvindran A/L AlagaOTHER_GOV | 1 | Jul 3, 2025 | clinicaltrials |
| NCT05989542 | A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)(KUNPENG-2) | recruiting | Phase 3 | 136 | Beijing Pearl Biotechnology Limited Liability CompanyINDUSTRY | 1 | Jun 29, 2025 | clinicaltrials |
| NCT05796973 | Measuring Oncological Value of Exercise and Statin(MOVES) | recruiting | Phase 3 | 240 | Tampere University HospitalOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT06980272 | SSGJ-707 in Advanced Non-Small Cell Lung Cancer | recruiting | Phase 3 | 420 | Shenyang Sunshine Pharmaceutical Co., LTD.INDUSTRY | 1 | Jun 24, 2025 | clinicaltrials |
| NCT07034326 | Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer | recruiting | Phase 2 / Phase 3 | 405 | Kong FanmingOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT06954246 | A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer | recruiting | Phase 3 | 450 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 18, 2025 | clinicaltrials |
| NCT07016126 | D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC | recruiting | Phase 3 | 70 | Guangdong Provincial People's HospitalOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT06754644 | A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC | recruiting | Phase 3 | 808 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 10, 2025 | clinicaltrials |
| NCT07008716 | Omitting CTV for Primary Tumor in LS-SCLC | recruiting | Phase 3 | 852 | Sun Yat-sen UniversityOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06235203 | Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC | recruiting | Phase 3 | 154 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT07000643 | Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma | recruiting | Phase 3 | 386 | Man HuOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT04328948 | A Randomized Controlled Trial Evaluating of Prophylactic Irradiation in CRT for cT1bN0M0 ESCC(ARMADILLO) | recruiting | Phase 3 | 280 | National Cancer Center, JapanOTHER_GOV | 1 | May 22, 2025 | clinicaltrials |
| NCT06749899 | QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma. | recruiting | Phase 3 | 580 | Sun Yat-Sen University Cancer CenterOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT03201861 | Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women | recruiting | Phase 3 | 762 | RenJi HospitalOTHER | 1 | May 16, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Nov 17, 2025source: clinicaltrials